+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Global Doxorubicin Market by Drug Formulation (Doxorubicin Injection, Lyophilized Powder), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), Application - Forecast 2024-2030

  • PDF Icon

    Report

  • 188 Pages
  • March 2024
  • Region: Global
  • 360iResearch™
  • ID: 5336666
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Doxorubicin Market size was estimated at USD 2.39 billion in 2023, USD 2.65 billion in 2024, and is expected to grow at a CAGR of 10.82% to reach USD 4.92 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Doxorubicin Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Doxorubicin Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Doxorubicin Market, highlighting leading vendors and their innovative profiles. These include AbbVie, Inc., Cadila Pharmaceuticals Ltd., Changzhou Kinyond Pharmaceutical Co., Ltd, Cipla, Inc., Dr. Reddy’s Laboratories Ltd., Getwell Oncology Pvt Ltd, Glenmark Pharmaceuticals Ltd., Intas Pharmaceuticals Limited, Ipsen S.A., Janssen Global Services, LLC By Johnson & Johnson Services, Inc., LGM Pharma, LLC, Manus Aktteva Biopharma LLP, Meiji Holdings Co., Ltd., Merrimack Pharmaceuticals, Inc., Novartis AG, Pfizer, Inc., SRS pharmaceuticals Pvt. Ltd., Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals, Thymoorgan Pharmazie GmbH, and TTY Biopharma.

Market Segmentation & Coverage

This research report categorizes the Doxorubicin Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Drug Formulation
    • Doxorubicin Injection
    • Lyophilized Powder
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
  • Application
    • Bone Sarcoma
    • Breast Cancer
    • Endometrial Cancer
    • Gastric Cancer
    • Kaposi Sarcoma
    • Kidney Cancer
    • Leukemia
    • Liver Cancer
    • Multiple Myeloma
    • Ovarian Cancer
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as

  1. What is the market size and forecast of the Doxorubicin Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Doxorubicin Market?
  3. What are the technology trends and regulatory frameworks in the Doxorubicin Market?
  4. What is the market share of the leading vendors in the Doxorubicin Market?
  5. Which modes and strategic moves are suitable for entering the Doxorubicin Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Frequently Asked Questions about the Global Doxorubicin Market

What is the estimated value of the Global Doxorubicin Market?

The Global Doxorubicin Market was estimated to be valued at $2.65 Billion in 2024.

What is the growth rate of the Global Doxorubicin Market?

The growth rate of the Global Doxorubicin Market is 10.8%, with an estimated value of $4.92 Billion by 2030.

What is the forecasted size of the Global Doxorubicin Market?

The Global Doxorubicin Market is estimated to be worth $4.92 Billion by 2030.

Who are the key companies in the Global Doxorubicin Market?

Key companies in the Global Doxorubicin Market include AbbVie, Inc., Cadila Pharmaceuticals Ltd., Changzhou Kinyond Pharmaceutical Co., Ltd, Cipla, Inc., Dr. Reddy’s Laboratories Ltd., Getwell Oncology Pvt Ltd, Glenmark Pharmaceuticals Ltd., Intas Pharmaceuticals Limited, Ipsen S.A. and Janssen Global Services, LLC By Johnson & Johnson Services, Inc..

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Doxorubicin Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing cancer incidence rate worldwide
5.1.1.2. Government approvals for use of doxorubicin against certain disorders
5.1.1.3. Growing effort towards increasing awareness and drug availability
5.1.2. Restraints
5.1.2.1. Changing regulatory frameworks
5.1.3. Opportunities
5.1.3.1. Ongoing research and development for novel drug discovery and development
5.1.3.2. Supportive government initiatives for cancer treatment and prevention
5.1.4. Challenges
5.1.4.1. Serious side effects of the drug
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Doxorubicin Market, by Drug Formulation
6.1. Introduction
6.2. Doxorubicin Injection
6.3. Lyophilized Powder
7. Doxorubicin Market, by Distribution Channel
7.1. Introduction
7.2. Hospital Pharmacy
7.3. Online Pharmacy
7.4. Retail Pharmacy
8. Doxorubicin Market, by Application
8.1. Introduction
8.2. Bone Sarcoma
8.3. Breast Cancer
8.4. Endometrial Cancer
8.5. Gastric Cancer
8.6. Kaposi Sarcoma
8.7. Kidney Cancer
8.8. Leukemia
8.9. Liver Cancer
8.10. Multiple Myeloma
8.11. Ovarian Cancer
9. Americas Doxorubicin Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Doxorubicin Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Doxorubicin Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. AbbVie, Inc.
13.1.2. Cadila Pharmaceuticals Ltd.
13.1.3. Changzhou Kinyond Pharmaceutical Co., Ltd
13.1.4. Cipla, Inc.
13.1.5. Dr. Reddy’s Laboratories Ltd.
13.1.6. Getwell Oncology Pvt Ltd
13.1.7. Glenmark Pharmaceuticals Ltd.
13.1.8. Intas Pharmaceuticals Limited
13.1.9. Ipsen S.A.
13.1.10. Janssen Global Services, LLC By Johnson & Johnson Services, Inc.
13.1.11. LGM Pharma, LLC
13.1.12. Manus Aktteva Biopharma LLP
13.1.13. Meiji Holdings Co., Ltd.
13.1.14. Merrimack Pharmaceuticals, Inc.
13.1.15. Novartis AG
13.1.16. Pfizer, Inc.
13.1.17. SRS pharmaceuticals Pvt. Ltd.
13.1.18. Sun Pharmaceutical Industries Ltd.
13.1.19. Teva Pharmaceuticals
13.1.20. Thymoorgan Pharmazie GmbH
13.1.21. TTY Biopharma
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
List of Figures
FIGURE 1. DOXORUBICIN MARKET RESEARCH PROCESS
FIGURE 2. DOXORUBICIN MARKET SIZE, 2023 VS 2030
FIGURE 3. DOXORUBICIN MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. DOXORUBICIN MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. DOXORUBICIN MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. DOXORUBICIN MARKET DYNAMICS
FIGURE 7. DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2023 VS 2030 (%)
FIGURE 8. DOXORUBICIN MARKET SIZE, BY DRUG FORMULATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
FIGURE 10. DOXORUBICIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. DOXORUBICIN MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 12. DOXORUBICIN MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS DOXORUBICIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS DOXORUBICIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES DOXORUBICIN MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES DOXORUBICIN MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC DOXORUBICIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC DOXORUBICIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA DOXORUBICIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA DOXORUBICIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. DOXORUBICIN MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. DOXORUBICIN MARKET SHARE, BY KEY PLAYER, 2023

Companies Mentioned

  • AbbVie, Inc.
  • Cadila Pharmaceuticals Ltd.
  • Changzhou Kinyond Pharmaceutical Co., Ltd
  • Cipla, Inc.
  • Dr. Reddy’s Laboratories Ltd.
  • Getwell Oncology Pvt Ltd
  • Glenmark Pharmaceuticals Ltd.
  • Intas Pharmaceuticals Limited
  • Ipsen S.A.
  • Janssen Global Services, LLC By Johnson & Johnson Services, Inc.
  • LGM Pharma, LLC
  • Manus Aktteva Biopharma LLP
  • Meiji Holdings Co., Ltd.
  • Merrimack Pharmaceuticals, Inc.
  • Novartis AG
  • Pfizer, Inc.
  • SRS pharmaceuticals Pvt. Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceuticals
  • Thymoorgan Pharmazie GmbH
  • TTY Biopharma

Methodology

Loading
LOADING...